중추신경계(CNS) 바이오마커 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Central Nervous System (CNS) Biomarkers Market size is expected to reach USD 15.01 Billion in 2034 from USD 7.14 Billion (2025) growing at a CAGR of 8.61% during 2026-2034.

The CNS biomarkers market is expanding as neurological and psychiatric disorder research intensifies. Biomarkers provide measurable indicators of disease progression, therapeutic response, and early diagnosis in conditions such as Alzheimer's, Parkinson's, epilepsy, and multiple sclerosis. Rising prevalence of CNS disorders, investment in drug development, and demand for personalized therapies are driving adoption across clinical, pharmaceutical, and research settings.

Technological innovation is fueling market growth. Advanced imaging, molecular, genetic, and proteomic techniques enable precise biomarker identification and monitoring. Integration with AI-driven analytics, high-throughput screening, and lab-on-a-chip platforms enhances predictive diagnostics, clinical trial efficiency, and patient stratification. Multiplex biomarker panels allow simultaneous assessment of multiple pathways, improving therapeutic decision-making and drug development outcomes.

Future growth is expected from increasing R&D investment, aging populations, and expansion of precision medicine initiatives. North America and Europe dominate due to mature clinical research infrastructure, while Asia-Pacific is witnessing rapid adoption fueled by expanding pharmaceutical and neuroscience research hubs. Collaborations between academic institutions, biotech firms, and pharmaceutical companies are accelerating biomarker discovery and validation. CNS biomarkers are poised to become integral tools in neurotherapeutics, enabling early intervention, personalized treatment, and improved patient outcomes.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Biomarker Type

• Safety Biomarker
• Efficacy Biomarker
• Validation Biomarker
• Other Biomarkers

By Application

• Disease Diagnosis
• Drug Discovery And Development
• Personalized Medicines
• Other Applications

By End-Use

• Hospitals & Clinics
• Diagnostic Laboratories
• Academic & Research Institutes
• Other End-Users

COMPANIES PROFILED

• bioMerieux, BioRad Laboratories Inc, F HoffmannLa Roche Ltd, GBiosciences, Illumina Inc, Merck KGaA, Myriad Genetics Inc, Novartis AG, PerkinElmer Inc, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY BIOMARKER TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Biomarker Type
• 4.2. Safety Biomarker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Efficacy Biomarker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Validation Biomarker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Biomarkers Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Application
• 5.2. Disease Diagnosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Drug Discovery And Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Personalized Medicines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY END-USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-use
• 6.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Academic & Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Other End-Users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Biomarker Type
  • 7.2.2 By Application
  • 7.2.3 By End-use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Biomarker Type
  • 7.3.2 By Application
  • 7.3.3 By End-use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Biomarker Type
  • 7.4.2 By Application
  • 7.4.3 By End-use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Biomarker Type
  • 7.5.2 By Application
  • 7.5.3 By End-use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Biomarker Type
  • 7.6.2 By Application
  • 7.6.3 By End-use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 BioMerieux
  • 9.2.2 Bio-Rad Laboratories Inc
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 G-Biosciences
  • 9.2.5 Illumina Inc
  • 9.2.6 Merck KGaA
  • 9.2.7 Myriad Genetics Inc
  • 9.2.8 Novartis AG
  • 9.2.9 PerkinElmer Inc
  • 9.2.10 Siemens Healthineers AG
  • 9.2.11 Sysmex Corporation
  • 9.2.12 Thermo Fisher Scientific Inc